# Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

> **NCT00477750** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 33 (actual)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** lenalidomide
- **DRUG:** melphalan
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT00477750
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2008-04
- **Final completion:** 2013-08-05
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2019-10-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00477750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00477750, "Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00477750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*